-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Equal-Weight on Summit Therapeutics, Lowers Price Target to $18

Benzinga·11/16/2026 15:54:06
Barclays analyst Etzer Darout maintains Summit Therapeutics (NASDAQ:SMMT) with a Equal-Weight and lowers the price target from $20 to $18.